Filters Resource type Area of interest Brochures & Flyers PhysioMimix Nash-in-a-box brochure NASH-in-a-box contains everything required to recreate our industry-validated in vitro human Non-Alcoholic Steatohepatitis (NASH) model in your own laboratory Brochures & Flyers Organ-on-a-chip Contract Research Services Brochure Discover our full range of Organ-on-a-chip contract research services including ADME, NASH, DILI and Oncology as well as all the relevant endpoints. Posters Modelling the intestine-liver axis: The role of FXR agonists in a multi-organ microphysiological system model of non-alcoholic fatty liver disease Here, we demonstrate the potential of a liver and a gut/liver microphysiological systems (MPS) to recapitulate NAFLD and NASH phenotypes in vitro and explore the molecular mechanisms underlying the development of NAFLD/NASH as well as assess the efficacy of novel therapeutic strategies. Webinars The Human Touch Webinar Series 5 Episode 4 In this webinar, we highlight how the liver-on-a-chip system can be used to assess the impact of HSD17B13 inhibitors on fibrosis, human metabolism and lipid droplets. Webinars The Dash for NASH Webinar Series 5 Episode 3 Find out how to: rapidly adopt an organ-on-a-chip (OOC) approach to NASH research, generate clinically translatable data from an industry-proven in vitro NASH model, and how OOC can help you unlock NASH disease mechanisms, and confirm drug efficacy and safety. Application notes Microphysiological system for studying fatty liver disease and its impact on drug-induced liver injury Kostrzewski et al As a result of the increased prevalence of diabetes, obesity, and metabolic syndrome, non-alcoholic fatty liver disease (NAFLD) is now the most common chronic liver disease in developed countries. Using better in vitro models to fast-track therapeutic development but also accurately assess DILI risk in NASH patients ahead of the clinic is critical. Here, we show the potential of an in vitro 3D NASH model to accurately identify any DILI-associated risks. Infographic Pros and cons of preclinical models of Non-Alcoholic Steatohepatitis This infographic was made by Biotechniques to help educate people on our NASH-in-a-box kit and how it sets a new standard in the search for an approved NASH therapeutic. Videos and animations In Focus: Modeling NASH disease – organ-on-a-chip technologies This short animation describes how our NASH-in-a-box kit enhances your chance of successfully developing NASH therapeutics by recreating our industry-proven NASH model in your laboratory. Created by Biotechniques. Podcasts Organ-on-a-Chip Models of Fatty Liver Disease 15-Minute Tech Blast – In this podcast developed by Biotechniques, our Lead Scientist Gareth Guenigault discussed NAFLD & NASH and their growing prevalence both in terms of cases and economic factors. Articles New Model Will Support Drug Discovery for Liver Disease NASH Dr Audrey Doubourg discusses the therapeutic challenges of NASH and how our NASH-in-a-box kit will help to advance drug discovery. This article is taken from Technology Networks, April 2022. Articles A pressing Need for Accurate Preclinical Models of Metabolic Disease How using organ-on-a-chip (OOC) can more accurately recapitulate the physiology and functions of the human body by culturing under flow perfusion – to mimic the blood – in 3D. This article is taken from European Biopharmaceutical Review January 2022, pages 28-31. Scientific publications β2-spectrin (SPTBN1) as a therapeutic target for diet-induced liver disease and preventing cancer development Rao et al., 2021 This study shows the effect of the presence of β2-spectrin (SPTBN1) in the promotion of sterol regulatory element (SRE)–binding protein (SREBP)–stimulated lipogenesis. These findings suggest SPTBN1 could be a potential target for a therapeutic against NASH and liver cancer.